There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioNTech SE (BNTX – Research Report) and AIM ImmunoTech (AIM – Research Report) with bullish sentiments.
BioNTech SE (BNTX)
Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on BioNTech SE today and set a price target of $200.00. The company’s shares closed last Thursday at $104.68, close to its 52-week low of $100.08.
According to TipRanks.com, Shu is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $157.23, a 49.4% upside from current levels. In a report released yesterday, Redburn Partners also upgraded the stock to Buy with a $170.00 price target.
See the top stocks recommended by analysts >>
AIM ImmunoTech (AIM)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on AIM ImmunoTech, with a price target of $3.00. The company’s shares closed last Thursday at $0.50.
According to TipRanks.com, McCarthy has 0 stars on 0-5 stars ranking scale with an average return of
AIM ImmunoTech has an analyst consensus of Moderate Buy, with a price target consensus of $4.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BNTX:
- BioNTech Rises on Q1 Beat
- BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
- Biontech Se Sponsored Adr (BNTX) Q1 Earnings Cheat Sheet
- BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
- Cantor biopharma/biotech analysts to hold an analyst/industry conference call
